Intellia Therapeutics Inc

Intellia Therapeutics Inc(NTLA)资讯与事件

$12.690

-0.039 (-0.31%)收盘时

NTLA 资讯

NTLA 事件

8/6 08:00

Intellia Q2 Revenue $7.66M, Below Consensus

Reports Q2 revenue $7.66M, consensus $12.98M. "The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema," said John Leonard, Intellia President and Chief Executive Officer. "These data serve as strong validation for in vivo gene editing and lonvo-z's potential to transform the treatment paradigm for patients who are burdened by this disease."

6/17 12:30

Intellia Therapeutics Stock Rises 12.9% to $16.43

Intellia Therapeutics is up 12.9%, or $1.88 to $16.43.

6/17 10:30

Intellia Therapeutics Stock Rises 10.7% to $16.11

Intellia Therapeutics is up 10.7%, or $1.56 to $16.11.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始